Personal or Pro, Dexcom G6 CGM Systems enhances your care.
Accuracy and outcomes
Dexcom G6 features an overall MARD¶ of 9.0%.1 Dexcom CGM use is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range.2,3,10-12
Real-time continuous glucose monitoring (RT-CGM)
Real-time glucose readings are sent straight to your patient's smart device* or receiver whenever, wherever.
ZERO FINGERSTICKS, CALIBRATION, OR SCANS‡
Neither Dexcom G6 Personal nor Pro require calibrations and both can be used to make treatment decisions without fingersticks.
When the Dexcom G6 Pro is used in unblinded mode, the Urgent Low Soon Alert can warn patients in advance of potentially dangerous low glucose values (55 mg/dL or below) and is associated with reduced hypoglycemia, without a corresponding increase in hyperglycemia.§,4
Your patients can choose to share their glucose data with up to 10|| followers. Should patients also give their followers the ability to receive alert notifications, followers can help patients stay in range.
Dexcom Clarity compatibility
Use of the Dexcom Clarity software and reports can facilitate better conversations about a patient’s Dexcom G6 glucose data during telehealth or in-person visits.
‡If your glucose alerts and readings from the Dexcom G6 CGM System do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
* Compatible smart devices sold separately: dexcom.com/compatibility.
† Mean absolute relative difference (MARD) is a statistical measure of accuracy.
§ This predictive alert can be triggered with impending hypoglycemia (glucose of 55 mg/dL or below is predicted to occur within the next 20 minutes).
|| Separate Dexcom Follow app required. Internet connectivity required for data sharing. Followers should always confirm readings on the Dexcom G6 app or receiver before making treatment decisions. Followers must have compatible smart devices to use the Dexcom Follow app.
1 Shah VN, et al. Diabetes Technol Ther. 2018;20(6):428-433.
2 Beck RW, et al. JAMA. 2017;317(4):371-378.
3 Welsh JB et al. Diabetes Technol Ther. 2019;21(3):128-132.
4 Puhr S, et al. Diabetes Technol Ther. 2019;21(4):155-158.